The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone

Clinical and Experimental Immunology

Volumn 106, Issue 2, 1996, Pages 243-252

  Macanovic, M ^a   Sinicropi, D ^b   Shak, S ^b   Baughman, S ^b   Thiru, S ^c   Lachmann, P J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b GENENTECH INC   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

anti DNA antibodies; dexamethasone; DNase; immune complexes; NZB W F1 mice; systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; DEOXYRIBONUCLEASE; DEXAMETHASONE; RECOMBINANT DNASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029851318     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-839.x     Document Type: Article

References (39)

1. Hargraves MM, Richmond H, Morton R, Presentation of two bone marrow elements, the 'Tart' cell and the 'LE' cell. Proc Staff Meet Mayo Clinic 1948; 23:25-28.
2. Haserick JR, Lewis LA, Bortz DW. Blood factor in acute disseminated lupus erythematosus. I Determination of gamma globulin as specific plasma fraction. Amer J Med Sci 1950; 219:660 3.
3. Miescher P, Fauconnet M. L'absorption du facteur 'LE' par les noyaux cellulaires isolés. Experimentia 1954; 10:252 4.
4. Ceppellini R, Polli E, Celada F. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol 1957; 95:572 4.
5. Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol 1957;96:575 9.
6. Seligmann M. Mise en évidence dans le serum de malades atteints de lupus érythémateux disséminé d'une substance déterminant une réaction de précipitation avec l'acide desoxyribonucleique. C R Acad Sci (Paris) 1957; 245:243 5.
7. Lachmann PJ. An attempt to characterise the lupus erythematosus cell antigen. Immunology 1961; 4:153 63.
8. Dixon FJ, Vazquez JJ, Weigle WO, Cochrane CG. Pathogenesis of serum sickness. A M A Arch Path 1958; 65:18 28.
9. Freedman P, Markowitz AS. Immunological studies in nephritis. Lancet 1959; ii:45 46.
10. Lachmann PJ. The immunological properties of cell nuclei with special reference to the serological aspects and pathogenesis of systemic lupus erythematosus. PhD thesis, University of Cambridge, 1961.
11. Johnson AJ, Goger PR, Tillett WS. Intravenous injection of crystal-line pancreatic desoxyribonuclease into patients. J Clin Invest 1954; 33:1670-86.
12. Johnson AJ, Ayvazian JH, Tillett WS. Crystalline pancreatic desoxyribonuclease as adjunct to treatment of pneumococcal meningitis. New Engl J Med 1959; 260:892-900.
13. Ayvazian JH, Ayvazian LF. The effect of crystalline pancreatic desoxyribonuclease in patients with gout. New Eng J Med 1960; 263:999-1002.
14. Lachmann PJ. Allergic reactions, connective tissue and disease. Sci Basis of Med Ann Rev 1967; 36-58.
15. Krishnan MR, Marion TN. Structural similarity of antibody variable regions from immune and autoimmune anti-DNA antibodies. J Imunol 1993; 150:4948 57.
16. Rumore P, Steinmann C. Endogenous circulating DNA in systemic lupus erythematosus: occurrence as multimeric complexes bound to histone. J Clin Invest 1990; 86:69-74.
17. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells in lupus. J Exp Med 1993; 177:1367-81.
18. Termaat RM, Assmann KJM, Dijkman HBPM, van Gompel F, Smeenk RJT, Berden JKM. Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 1992; 42:1363-71.
19. Bernstein KA, Valerio RD, Lefkowith J. Glomerular binding activity in MRL 1pr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J Immunol 1995; 154:2424-33.
20. Kramers C, Hylkema MN, van Bruggen MC, van de Lagemaat R, Dijkman HB, Assmann KJ, Smeenk RJ, Berden JH. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994; 94:568 77.
21. Kalden JR. Pathogenic aspects of systemic lupus erythematosus. Behring Inst Mitt 1992; 91:197-203.
22. Schmiedeke T, Stoeckl F, Muller S, Sugisaki Y, Batsford S, Woitasand R, Vogt A. Glomerular immune deposits in murine lupus models may contain histones. Clin Exp Immunol 1992; 90:453 8.
23. van Bruggen MC, Kramers C, Hylkema MN, Smeenk RJ, Berden JH. Pathophysiology of lupus nephritis: the role of nucleosomes. The Neth J Med 1994; 45:273 9.
24. Lachmann PJ, Walport MJ. Deficiency of the effector mechanisms of the immune response and autoimmnunity. In: Whelan J, ed. Autoimmunity and autoimmune disease. Ciba Foundation Symposium 129. Chichester: Wiley Ltd, 1987: 149.
25. Steinsson K, Erlendsson K, Valdimarsson H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum 1989; 32:906 13.
26. Belmont HM, Buton J, Giorno R, Abramson SB. Complement activation, adhesion molecules and vascular injury. Abstracts from the Fourth International Conference on systemic LE. Lupus 1995; 4(Suppl. 2):8 (Abstr.).
27. Biro CE. Algunos conceptos immunologicos en relacion eon la patogenia del lupus eritematoso deseminado. Arch Inst Cardiol Mex 1967; 37:669-74.
28. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease 1. Proc Natl Acad Sci USA 1974; 71:4742 6.
29. Frost PG, Lachmann PJ. The relationship of deoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol 1968; 3:447 55.
30. Hadjiyannaki K, Lachmann PJ. The relation of deoxyribonuclease inhibitor levels to the occurrence of antinuclear antibodies in NZB/ NZW mice. Clin Exp Immunol 1972; 11:292 5.
31. Lacks SA. Deoxyribonuclease I in mammalian tissues. J Biol Chem 1981; 256:2644 8.
32. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87:9188-92.
33. Walker SE, Anver MR, Sclechter SL, Bole GG. Prolonged lifespan and high incidence of neoplasms in NZB/NZW mice treated with hydrocortisone sodium succinate. Kidney Int 1978; 14:151 7.
34. Cupps TR, Fauci AS. Corticosteroid immunomodulation in man. Immunol Rev 1982; 65:133-55.
35. Mason D. The roles of the hypothalamus and the gastrointestinal tract in the prevention of inflammatory autoimmune disease. Editorial Review. Clin Exp Immunol 1978; 97:339 41.
36. Puccetti A, Madaio MP, Bellese G, Migliorini P. Anti-DNA antibodies bind to DNase 1. J Exp Med 1995; 181:1797 804.
37. Izui S, Lambert PH, Miescher PA. Failure to detect circulating DNA/anti-DNA complexes by four radioimmunochemical methods in patients with systemic LE. Clin Exp Immunol 1977; 30:384-92.
38. Valim YML, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 1991; 84:1-8.
39. Zhang W, Voice J, Lachmann PJ. A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes. Clin Exp Immunol 1995; 101:507 15.